# Pathological Response After Neoadjuvant Treatment on NSCLC

> **NCT05167487** · — · RECRUITING · sponsor: **Fundación GECP** · enrollment: 150 (estimated)

## Conditions studied

- Stage IIIA Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05167487
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-13
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167487, "Pathological Response After Neoadjuvant Treatment on NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05167487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*